<DOC>
	<DOCNO>NCT02237261</DOCNO>
	<brief_summary>The purpose study improve efficacy treatment patient newly diagnose multiple myeloma eligible high-dose chemotherapy follow autologous stem cell transplantation Bendamustin , Bortezomib ( Velcade ) , Prednisone .</brief_summary>
	<brief_title>Bendamustine , Prednisone Velcade® First-line Treatment Patients With Symptomatic Multiple Myeloma</brief_title>
	<detailed_description>1 . Objectives Primary -Therapeutic efficacy BPV regimen multiple myeloma evidence overall response define partial response ( PR ) good Secondary - ass overall survival ( OS ) progression-free survival ( PFS ) - determine response duration - investigate improvement renal function - evaluate safety toxicity ( respect adverse event CTCAE grade ≧3 SAEs ) - analyze efficacy genetically define subgroup myeloma patient base iFISH gene-expression profile 2 . Investigational Medicinal Products Bortezomib Bendamustine combination Prednisone</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Newly diagnose multiple myeloma require systemic treatment ( accord CRAB criterion specify appendix I ) follow characteristic : Subject candidate highdose chemotherapy stem cell transplantation due age , presence comorbidities likely negative impact tolerability HDTSCT , subject preference 2 . Measurable disease , define quantifiable monoclonal protein value , define least one follow three measurement ( Durie et al. , 2006 ) : Serum Mprotein ≥ 10g/l Urine lightchain ( Mprotein ) ≥ 200 mg/24 hour Serum FLC assay : involve FLC level ≥ 10 mg/dl provide sFLC ratio abnormal 3 . Age &gt; 18 year 4. WHO performance status 03 ( WHO=3 allow related MM comorbid condition ) ( see appendix III ) 5 . For woman childbearing potential : negative pregnancy test inclusion 6 . All patient must willing capable use adequate contraception complete therapy . 7 . All patient must agree abstain donate blood study 8 . Ability understand character individual consequence clinical trial 9 . Written informed consent ( must available enrolment trial ) Subjects present follow criterion include trial 1 . Patient known hypersensitivity bortezomib , bendamustine prednisone constituent compound ( incl . boron mannitol ) . 2 . Systemic AL amyloidosis ( except patient AL amyloidosis skin bone marrow ) 3 . Chemotherapy radiotherapy past 5 year except patient local radiotherapy case local myeloma progression . ( Note : patient may receive cumulative dose 160 mg dexamethasone equivalent emergency therapy within 3 week prior study entry . ) 4 . Plasma cell leukemia require presence 20 % plasma cell peripheral blood leukocyte least 2 plasma cells/nl . 5 . Severe cardiac dysfunction ( NYHA classification IIIIV , see appendix III ) 6 . Significant hepatic dysfunction ( serum bilirubin ≥ 2 mg/dl ASAT and/or ALAT ≥ 2.5 time normal level ) , unless relate myeloma 7 . Patients know HIVpositive 8 . Patients active , uncontrolled infection 9 . Patients peripheral neuropathy neuropathic pain CTC grade 2 high ( define NCI Common Terminology Criteria Adverse Events ( NCI CTCAE ) Version 4.0 , see appendix V ) 10 . Second malignancy past 5 year except : Adequately treat basal cell squamous cell skin cancer , Carcinoma situ cervix , Prostate cancer &lt; Gleason score 6 undetectable prostatespecific antigen ( PSA ) 12 month , Ductal breast carcinoma situ full surgical resection ( i.e. , negative margin ) , Similar malignant condition a. d. expected5year disease free survival large 95 % 11 . Patients acute diffuse infiltrative pulmonary pericardial disease 12 . Autoimmune hemolytic anemia positive Coombs test immune thrombocytopenia 13 . Platelet count &lt; 50 x 109/l ( transfusion support within 14 day test allow ) , unless relate myeloma 14 . Hemoglobin &lt; 7.5g/dl , unless relate myeloma 15 . Absolute neutrophil count ( ANC ) &lt; 0.75 x 109/l ( use colony stimulate factor within 14 day test allow ) , unless relate myeloma 16 . Pregnancy lactation 17 . Participation clinical trial within one month prior enrolment except supportive care study vaccination study . ( Note : include longterm followup period without active drug treatment previous study last 6 month ) . No subject allow enrol trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Newly diagnose symptomatic multiple myeloma</keyword>
</DOC>